Modifying tumor-associated macrophages: An important adjunct to immunotherapy

Zvi G. Fridlender; Steven M. Albelda

doi:10.4161/onci.26620

Modifying tumor-associated macrophages: An important adjunct to immunotherapy

Zvi G. Fridlender^*, Steven M. Albelda

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials.

Original language	English
Article number	e26620
Journal	OncoImmunology
Volume	2
Issue number	12
DOIs	https://doi.org/10.4161/onci.26620
State	Published - 2013
Externally published	Yes

Keywords

DMXAA
Immunotherapy
Lung cancer
Tumor associated macrophages
Vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/onci.26620

Cite this

@article{6f826cf4495a4bf9bc1e70577f20f5e3,

title = "Modifying tumor-associated macrophages: An important adjunct to immunotherapy",

abstract = "The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials.",

keywords = "DMXAA, Immunotherapy, Lung cancer, Tumor associated macrophages, Vaccines",

author = "Fridlender, {Zvi G.} and Albelda, {Steven M.}",

year = "2013",

doi = "10.4161/onci.26620",

language = "אנגלית",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "12",

}

TY - JOUR

T1 - Modifying tumor-associated macrophages

T2 - An important adjunct to immunotherapy

AU - Fridlender, Zvi G.

AU - Albelda, Steven M.

PY - 2013

Y1 - 2013

N2 - The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials.

AB - The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials.

KW - DMXAA

KW - Immunotherapy

KW - Lung cancer

KW - Tumor associated macrophages

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84896718700&partnerID=8YFLogxK

U2 - 10.4161/onci.26620

DO - 10.4161/onci.26620

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:84896718700

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 12

M1 - e26620

ER -

Modifying tumor-associated macrophages: An important adjunct to immunotherapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this